VistaGen Therapeutics
VTGN
49 hedge funds and large institutions have $2.54M invested in VistaGen Therapeutics in 2026 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 16 closing their positions.
941% more call options, than puts
Call options by funds: $333K | Put options by funds: $32K
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
8.48% less ownership
Funds ownership: 37.18% → 28.7% (-8.5%)
13% less funds holding
Funds holding: 56 → 49 (-7)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
69% less capital invested
Capital invested by funds: $8.12M → $2.54M (-$5.58M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
+$1.68M |
| 2 |
Renaissance Technologies
New York
|
+$265K |
| 3 |
Two Sigma Investments
New York
|
+$228K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$172K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.75M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1.53M |
| 3 |
Millennium Management
New York
|
-$260K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$241K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$86K |
VTGN Hedge Fund Activity: Q2 2026 in Review
49 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2026, worth a combined $2.54M — down 69% from $8.12M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of VTGN and 10 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 15 added.
The largest buyer was Commodore Capital, opening a new position worth an estimated $1.68M. The largest seller was OrbiMed, exiting entirely with an estimated $1.75M sold.
- 49 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2026, down from 56 in Q1 2026.
- Funds reported $2.54M of VistaGen Therapeutics stock for Q2 2026, down 69% quarter-over-quarter.
- 10 funds opened new VistaGen Therapeutics positions in Q2 2026 and 16 closed out, a net change of -6 holders.
- The largest VistaGen Therapeutics buyer in Q2 2026 was Commodore Capital, an estimated $1.68M added.
- The largest VistaGen Therapeutics seller in Q2 2026 was OrbiMed, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2026.